(Q38484370)

3 September 2017

1 reference

title

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications (English)

1 reference

major depressive disorder

3 September 2017

1 reference

Chiara Fabbri

1

0 references

Alessandro Serretti

object named as

Alessandro Serretti

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 July 2015

1 reference

Current Psychiatry Reports

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

7

1 reference

3 September 2017

50

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-015-0594-9

3 September 2017

0 references

cites work

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

National patterns in antidepressant medication treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Pharmacogenetic response to antidepressants in a multicase family with affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Contribution of common genetic variants to antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A genomewide association study of citalopram response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Pharmacogenetics in major depression: a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Analysis of 34 candidate genes in bupropion and placebo remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Serotonin transporter gene variants and behavior: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Population genetic study of the brain-derived neurotrophic factor (BDNF) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Akt/GSK3 signaling in the action of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

DNA sequence variants of the FKBP5 gene are associated with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Quantitative pharmacogenetics of nortriptyline: a novel approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Sequence-based CYP2D6 genotyping in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Pathway-based analysis tools for complex diseases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A genome-wide association study of a sustained pattern of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A significantly increased number and percentage of B cells in depressed subjects: results of flow cytometric measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Neuroplasticity in the olfactory system: differential effects of central and peripheral lesions of the primary olfactory pathway on the expression of B-50/GAP43 and the olfactory marker protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Long-term potentiation and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Stress, depression, and neuroplasticity: a convergence of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Wnt2 expression and signaling is increased by different classes of antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Increased hippocampal neurogenesis and p21 expression in depression: dependent on antidepressants, sex, age, and antipsychotic exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Gender differences in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Transcriptional evidence for the role of chronic venlafaxine treatment in neurotrophic signaling and neuroplasticity including also Glutamatergic [corrected] - and insulin-mediated neuronal processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The negative cell cycle regulator, Tob (transducer of ErbB-2), is a multifunctional protein involved in hippocampus-dependent learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Specific regulation of NRG1 isoform expression by neuronal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant Adeno-associated viral gene delivery of Homer1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Understanding the pharmacogenetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

Neuronal cell adhesion genes and antidepressant response in three independent samples

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11920-015-0594-9

21 January 2018

12 December 2020

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort

1 reference

12 December 2020

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients

1 reference

12 December 2020

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response

1 reference

12 December 2020

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

12 December 2020

Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment

1 reference

12 December 2020

Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding

1 reference

12 December 2020

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

1 reference

12 December 2020

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway

1 reference

12 December 2020

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

1 reference

12 December 2020

Allelic variation of human serotonin transporter gene expression

1 reference

12 December 2020

Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression.

1 reference

12 December 2020

BDNF Val66Met genotype and 6-month remission rates in late-life depression

1 reference

12 December 2020

Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis

1 reference

12 December 2020

A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels

1 reference

12 December 2020

Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees

1 reference

12 December 2020

GAP43 phosphorylation is critical for growth and branching of retinotectal arbors in zebrafish.

1 reference

12 December 2020

FKBP5 polymorphisms and antidepressant response in geriatric depression

1 reference

12 December 2020

ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline

1 reference

12 December 2020

Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline

1 reference

12 December 2020

Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology.

1 reference

12 December 2020

Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment

1 reference

12 December 2020

Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

1 reference

12 December 2020

Variation in GNB3 predicts response and adverse reactions to antidepressants

1 reference

12 December 2020

5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.

1 reference

12 December 2020

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

1 reference

12 December 2020

Differentiation of two genetically specific types of depression by the response to anti-depressants

1 reference

12 December 2020

Genome-wide association studies of antidepressant outcome: a brief review

1 reference

12 December 2020

Beware of risk for increased false positive rates in genome-wide association studies for phenotypic variability.

1 reference

12 December 2020

10.1007/S11920-015-0594-9

Identifiers

DOI

1 reference

PubMed ID

25980509

Dimensions Publication ID

3 September 2017

1046948355

0 references

Fatcat ID

release_iiuyjuwoajb3vijn3svpjhmn7q

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iiuyjuwoajb3vijn3svpjhmn7q

24 November 2022

mapped directly with Wikidata item

PubMed ID

25980509

1 reference

PubMed ID

25980509